By targeting the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor (GCGR) simultaneously, Retatrutide provides a unique model for investigating systemic energy expenditure
Most patients report mild discomfort, like a pinprick or light burning, during injection
Symptoms vary from patient to patient, and often mimic the signs of other chronic conditions
Keep in mind, Tesamorelin lasts a little bit longer than Sermorelin
When you stop taking either drug, your blood sugar may rise and you may gain weight
If you have established atherosclerotic cardiovascular disease, your healthcare provider will likely recommend one of these agents with proven cardiovascular benefit